Key facts
- This page summarizes David Paul Keenan's Form 3 filing for AMARIN CORP PLC\UK (AMRN).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 31 Oct 2025, 16:30.
David Paul Keenan - 17 Oct 2025 Form 3 Insider Report for AMARIN CORP PLC\UK (AMRN)
- Reporting relationship
- EVP, Chief Operating Officer
- Issuer ticker
- AMRN
- Reported as of
- 17 Oct 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 31 Oct 2025, 16:30:06 UTC
- Next SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Provoost, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Paul Keenan filed Form 3 for AMARIN CORP PLC\UK (AMRN) on 31 Oct 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002094574
Primary reporting owner
Keenan David Paul
- Relationship
- EVP, Chief Operating Officer
- Address
- C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER
- Signature
- /s/ Jonathan Provoost, by power of attorney
- Signature date
- 31 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMRN
holding
American Depositary Share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,950
- Date
- 17 Oct 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMRN
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 6,740
- Exercise price
- $0.000000
- Footnotes
- F1, F2, F3, F4
AMRN
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 5,800
- Exercise price
- $0.000000
- Footnotes
- F1, F2, F4, F5
AMRN
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 7,376
- Exercise price
- $0.000000
- Footnotes
- F1, F2, F4, F6
AMRN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 33,193
- Exercise price
- $12.40
- Footnotes
- F1, F7, F8
AMRN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 20,900
- Exercise price
- $24.20
- Footnotes
- F1, F8, F9
AMRN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 13,480
- Exercise price
- $36.00
- Footnotes
- F1, F8, F10
AMRN
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Oct 2025
- Ownership
- Direct
- Underlying class
- American Depositary Share
- Underlying amount
- 5,000
- Exercise price
- $29.00
- Footnotes
- F1, F8, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 3 reflect the ADS Ratio Change.
Footnote F2
Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
Footnote F3
On February 21, 2023, the Reporting Person was granted 6,740 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2024, January 31, 2025 and January 31, 2026.
Footnote F4
Not applicable.
Footnote F5
On February 1, 2024, the Reporting Person was granted 5,800 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2025, January 31, 2026 and January 31, 2027.
Footnote F6
On January 10, 2025, the Reporting Person was granted 7,376 RSUs under the Plan. These RSUs vest over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
Footnote F7
On January 10, 2025, the Reporting Person was granted an option to purchase 33,193 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over eighteen months, with 50% to vest on the first anniversary of the grant date and the remaining balance to vest eighteen months after grant date.
Footnote F8
Grant price is set at the higher of (1) our nominal par value of 50 pence per share, as converted on date of grant, for which our Plan dictates under United Kingdom law, or (2) fair market value of stock price on the NASDAQ at close of business day.
Footnote F9
On February 1, 2024, the Reporting Person was granted an option to purchase 20,900 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
Footnote F10
On February 21, 2023, the Reporting Person was granted an option to purchase 13,480 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the last day of each April, July, October and January.
Footnote F11
On June 1, 2022, the Reporting Person was granted an option to purchase 5,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable over four years, with 25% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 12 calendar quarters on the last day of each April, July, October and January.